Results 161 to 170 of about 27,856 (310)

Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible
Stephanie A. Schultz   +26 more
wiley   +1 more source

CSF proteomic profiling with amyloid and tau pathology identifies distinctive sex‐specific alteration of multiple proteins involved in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION In Alzheimer's disease (AD), females have higher prevalence and faster progression, but sex‐specific molecular findings in AD are limited. METHODS We comprehensively examined 6162 proteins in cerebrospinal fluid (CSF) from 2496 participants to identify sex‐specific proteomic alteration by CSF amyloid beta (Aβ)42 and phosphorylated
Anh N. Do   +17 more
wiley   +1 more source

Defining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Amyloid‐induced tauopathy drives clinical decline in Alzheimer's disease (AD). Because age and sex shape tau trajectories, defining patient‐centered amyloid thresholds for tauopathy onset could facilitate pre‐tauopathy AD identification and aid treatment decisions and prognosis.
Zeyu Zhu   +21 more
wiley   +1 more source

DAP12 deletion reduces neuronal SLIT2 and demyelination and enhances brain resilience in female tauopathy mice [PDF]

open access: gold
Hao Chen   +21 more
openalex   +1 more source

Identifying early changes in imaging, plasma, and digital cognitive biomarkers that correspond to Alzheimer's disease pathology in the presence of autopsy‐confirmed co‐pathologies

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) biomarkers are assessed on their ability to detect AD pathophysiology in vivo, with confirmation of AD neuropathology only at autopsy. METHODS Positron emission tomography (PET), plasma, and cognitive AD biomarkers were compared to AD neuropathology in Harvard Aging Brain Study participants (10 cognitively
Charles D. Chen   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy